- Home
- APH vs VRTX Comparison
APH vs VRTX Comparison
Compare APH & VRTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- APH
- VRTX
- Stock Information
- Founded
- APH 1932
- VRTX 1989
- Country
- APH United States
- VRTX United States
- Employees
- APH N/A
- VRTX N/A
- Industry
- APH Electrical Products
- VRTX EDP Services
- Sector
- APH Technology
- VRTX Technology
- Exchange
- APH Nasdaq
- VRTX Nasdaq
- Market Cap
- APH 97.1B
- VRTX 115.6B
- IPO Year
- APH 1991
- VRTX 1991
- Fundamental
- Price
- APH $89.87
- VRTX $442.05
- Analyst Decision
- APH Buy
- VRTX Buy
- Analyst Count
- APH 12
- VRTX 26
- Target Price
- APH $82.75
- VRTX $512.54
- AVG Volume (30 Days)
- APH 7.7M
- VRTX 2.2M
- Earning Date
- APH 07-23-2025
- VRTX 05-05-2025
- Dividend Yield
- APH 0.73%
- VRTX N/A
- EPS Growth
- APH 25.95
- VRTX N/A
- EPS
- APH 2.06
- VRTX N/A
- Revenue
- APH $16,777,400,000.00
- VRTX $11,099,700,000.00
- Revenue This Year
- APH $34.08
- VRTX $10.36
- Revenue Next Year
- APH $7.50
- VRTX $10.61
- P/E Ratio
- APH $43.66
- VRTX N/A
- Revenue Growth
- APH 30.70
- VRTX 8.98
- 52 Week Low
- APH $54.77
- VRTX $377.85
- 52 Week High
- APH $89.98
- VRTX $519.88
- Technical
- Relative Strength Index (RSI)
- APH 78.73
- VRTX 43.63
- Support Level
- APH $83.44
- VRTX $427.43
- Resistance Level
- APH $87.22
- VRTX $451.64
- Average True Range (ATR)
- APH 1.54
- VRTX 10.29
- MACD
- APH -0.12
- VRTX 2.22
- Stochastic Oscillator
- APH 98.45
- VRTX 72.63
About APH Amphenol Corporation
Amphenol is a global supplier of connectors, sensors, and interconnect systems. Amphenol holds the second-largest connector market share globally and sells into the end markets of automotive, broadband, commercial air, industrial, IT and data communications, military, mobile devices, and mobile networks. Amphenol is diversified geographically, with operations in 40 countries.
About VRTX Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through Casgevy, a gene-editing therapy for beta thalassemia and sickle-cell disease. Additionally, Vertex is evaluating small-molecule inhibitors targeting acute and chronic pain using nonopioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.